NASDAQ : BCAX
Bicara Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 9.13 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 604.16M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 524.75M |
| Enterprise Value | 28.66M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 66.17M |
| Shares Outstanding | 66.17M |
| Shares Change (YoY) | +36.51% |
| Shares Change (QoQ) | +11.87% |
| Owned by Insiders (%) | 1.84% |
| Owned by Institutions (%) | 67.70% |
| Float | 36.90M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.28 |
| P/TBV Ratio | 1.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.59 |
| Quick Ratio | 11.44 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -41.01% |
| Return on Assets (ROA) | -26.14% |
| Return on Invested Capital (ROIC) | -27.83% |
| Return on Capital Employed (ROCE) | -43.09% |
| Weighted Average Cost of Capital (WACC) | 2.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.80M |
| Employee Count | 103 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 208,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.34 |
| 52-Week Price Change | -51.20% |
| 50-Day Moving Average | 19.42 |
| 200-Day Moving Average | 21.16 |
| Relative Strength Index (RSI) | 15.86 |
| Average Volume (20 Days) | 1,961,216 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.30M |
| Short Previous Month | 10.69M |
| Short % of Shares Out | 15.56% |
| Short % of Float | 27.91% |
| Short Ratio (days to cover) | 12.38 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -201.99M |
| Pretax Income | -185.16M |
| Net Income | -185.36M |
| EBITDA | -201.83M |
| EBIT | -201.99M |
| Earnings Per Share (EPS) | -$3.11 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 497.26M |
| Total Debt | 1.16M |
| Net Cash | 496.10M |
| Net Cash Per Share | $7.50 |
| Equity (Book Value) | 468.77M |
| Book Value Per Share | 7.11 |
| Working Capital | 460.35M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -134.85M |
| Capital Expenditures | -400,000 |
| Depreciation & Amortization | 155,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -135.25M |
| FCF Per Share | -$2.04 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -36.51% |
| Shareholder Yield | -36.51% |
| Earnings Yield | -39.21% |
| FCF Yield | -25.30% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $33.92 |
| Price Target Difference | 327.74% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |